Scarica l'app Stockscreener
120.39
3.58%
4.16
Dopo l'orario di chiusura:
120.50
0.11
+0.09%
Precedente Chiudi:
$116.23
Aprire:
$118.13
Volume 24 ore:
261.55K
Relative Volume:
0.84
Capitalizzazione di mercato:
$1.71B
Reddito:
$1.30M
Utile/perdita netta:
$-35.78M
Rapporto P/E:
-18.35
EPS:
-6.5624
Flusso di cassa netto:
$-22.82M
1 W Prestazione:
+5.39%
1M Prestazione:
-6.38%
6M Prestazione:
+108.68%
1 anno Prestazione:
+341.47%
Intervallo 1D:
$116.80
$123.94
Intervallo di 1 settimana:
$109.36
$123.94
Portata 52W:
$18.23
$151.18
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Nome
Palvella Therapeutics Inc
Settore
Industria
Telefono
(484) 253-1461
Indirizzo
353 W. LANCASTER AVENUE, WAYNE
Compare PVLA vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
120.39 | 1.65B | 1.30M | -35.78M | -22.82M | -6.5624 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Iniziato | Mizuho | Outperform |
| 2025-12-05 | Iniziato | BTIG Research | Buy |
| 2025-12-04 | Iniziato | Craig Hallum | Buy |
| 2025-11-19 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2025-09-09 | Iniziato | Oppenheimer | Outperform |
| 2025-08-06 | Iniziato | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-04-09 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-26 | Iniziato | Stifel | Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-20 | Iniziato | Canaccord Genuity | Buy |
| 2025-02-05 | Iniziato | TD Cowen | Buy |
| 2024-12-26 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-03-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | Iniziato | Robert W. Baird | Outperform |
| 2018-03-19 | Iniziato | Evercore ISI | Outperform |
| 2018-03-19 | Iniziato | Jefferies | Buy |
| 2018-01-16 | Reiterato | H.C. Wainwright | Buy |
| 2017-05-30 | Iniziato | Rodman & Renshaw | Buy |
| 2016-08-05 | Ripresa | ROTH Capital | Buy |
| 2015-08-12 | Iniziato | JMP Securities | Mkt Outperform |
| 2015-07-27 | Iniziato | Oppenheimer | Outperform |
| 2015-07-22 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Palvella Therapeutics Inc Borsa (PVLA) Ultime notizie
Palvella Stock Up 340% as Insider Sells Shares. Here's What the Move Does (And Does Not) Signal - The Motley Fool
Palvella Stock Up 340% as Insider Sells Shares. Here's What the Move Does (And Does Not) Signal - The Motley Fool
Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026 - Sahm
Director Buys $500,000 Worth of Palvella Therapeutics Shares After Phase 3 Win - AOL.com
European Patent Office grants Palvella patent for QTORIN rapamycin - MSN
H.C. Wainwright raises Palvella Therapeutics stock price target to $270 By Investing.com - Investing.com Canada
Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $270.00 at HC Wainwright - MarketBeat
European Patent Office Grants Palvella Patent for QTORIN Rapamycin - MyChesCo
Palvella appoints Jennifer McDonough as market access head By Investing.com - Investing.com Australia
Palvella Therapeutics Appoints Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services - citybiz
Palvella appoints Jennifer McDonough as market access head - Investing.com
Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services - The Manila Times
Palvella Therapeutics (PVLA) to Release Earnings on Monday - MarketBeat
Palvella Therapeutics (PVLA) Receives a Rating Update from a Top Analyst - The Globe and Mail
Rate Cut: Is Palvella Therapeutics Inc a play on infrastructure spending2026 Trade Ideas & Scalable Portfolio Growth Ideas - baoquankhu1.vn
Aug Shorts: Is Palvella Therapeutics Inc stock forming a cup and handle2026 Dividend Review & Low Risk Investment Opportunities - baoquankhu1.vn
Palvella Completes Phase 2 Trial of QTORIN Rapamycin for Rare Skin Disorder - MSN
Palvella Therapeutics COO sells $507k in shares By Investing.com - Investing.com India
Market Outlook: Can Palvella Therapeutics Inc lead its sector in growthWeekly Risk Summary & Advanced Technical Signal Analysis - baoquankhu1.vn
Palvella Therapeutics COO sells $507k in shares - Investing.com
Kathleen Goin Sells 4,302 Shares of Palvella Therapeutics (NASDAQ:PVLA) Stock - MarketBeat
Market Trends: Will Palvella Therapeutics Inc benefit from rising consumer demandPortfolio Value Summary & Low Risk High Win Rate Picks - baoquankhu1.vn
Palvella Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | PI6 | US6979471090 - marketscreener.com
Topical statins show promise for rare skin disease in new review - MSN
Clear Street initiates coverage of Palvella Therapeutics (PVLA) with buy recommendation - MSN
Fred Alger Management LLC Increases Stock Holdings in Palvella Therapeutics, Inc. $PVLA - MarketBeat
Palvella Therapeutics: A Potential First-In-Class Therapy In A Rare Dermatology Market - Seeking Alpha
Palvella receives European patent for rapamycin gel formulation By Investing.com - Investing.com India
Palvella Therapeutics stock price target maintained at $220 by Clear Street - Investing.com Nigeria
Palvella Therapeutics (NASDAQ:PVLA) Earns Buy Rating from Chardan Capital - MarketBeat
Palvella Therapeutics launches awareness campaign for rare lymphatic disease - MSN
Palvella Therapeutics stock price target maintained at $220 by Clear Street By Investing.com - Investing.com India
Palvella Therapeutics Launches Awareness Campaign for Rare Lymphatic Disease - MyChesCo
Palvella receives European patent for rapamycin gel formulation - Investing.com
Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin - GlobeNewswire
First Light Asset Management LLC Buys New Holdings in Palvella Therapeutics, Inc. $PVLA - MarketBeat
Apis Capital Advisors LLC Makes New Investment in Palvella Therapeutics, Inc. $PVLA - MarketBeat
Suvretta Capital Management LLC Boosts Stock Position in Palvella Therapeutics, Inc. $PVLA - MarketBeat
Palvella Therapeutics (NASDAQ:PVLA) Shares Down 8.7%Should You Sell? - MarketBeat
Palvella launches disease awareness campaign for rare lymphatic condition - Investing.com Nigeria
Quarterly Earnings: Can Palvella Therapeutics Inc lead its sector in growth2026 Price Swings & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Chipmakers Recap: Can Palvella Therapeutics Inc deliver alphaQuarterly Market Summary & Low Drawdown Investment Ideas - baoquankhu1.vn
Palvella launches disease awareness campaign for rare lymphatic condition By Investing.com - Investing.com South Africa
Palvella Therapeutics stock rating maintained at Buy by Clear Street - Investing.com Nigeria
Palvella Therapeutics Launches "BEYOND mLM" Disease - GlobeNewswire
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Palvella Therapeutics Reports Q1 2025 Financials and Clinical Progress - MSN
Palvella Therapeutics Inc Azioni (PVLA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):